The Ursinus Weekly, November 4, 1963

Speech by local leader highlights Founders Day • AAUW to meet on Ursinus campus • Dr. Robert Howard named to Who\u27s who • 40 music lovers to hear concert • Quaker journalist to present lecture on Cuban visit • Election of queen to begin Homecoming festivities • Peace pilgrim visits campus • Improved Lantern planned by editors • Folk singer to appear at UC Friday night • IFC plans party as Homecoming opener • Summer reading sessions end • New officer to present Wave program Nov. 7 • Items from abroad • Letters to the editor • Foreign students give views of US • Main Line Symphony announces guest soloist • Dear Wormwood cast in rehearsal • Youth organizes for Goldwater • Greek gleanings • Student organizing group to work at St. Gabriel\u27s • MSGA busy with many new projects • Mrs. Parsons to address Ursinus Circle Nov. 7 • Bears run into Seahawk deepfreeze • Intramural corner • Interview: Bob Mashock • Soccer team set back despite fine efforts • UC hockey teams win againhttps://digitalcommons.ursinus.edu/weekly/1256/thumbnail.jp

The Ursinus Weekly, May 13, 1963

Bears annex first MAC championship • Cold weather doesn\u27t freeze Mississippi mud • Senior show slated for May 16 • Sir George Thomson, famed physicist, to speak at Commencement exercises • Joyce Maloney wins title of Miss Montgomery County • Registration open for Summer school • Angelo Cutone, custodian, plans return to Italy • Pre-med society selects officers • Music Club names 1963-64 officers • Shinnick, Kelly, Gould elected class presidents • Whitians elect 1963-64 leaders • Dr. Steere urges understanding • Peggy Cooper new head cheerleader • GOP elects officers • New officers • As Helfferich leaves Girard Trust • Greek gleanings • UC Band presents Spring concert • Minutes of MSGA • Tibetan lamas • Fine casting and producing lead Staring match to success • Ursinus smites fiery Dragons 8-1; Bears give explorers victory 9-5 • Tennis team trims the Main Line • Jim Egolf: Freshman find • Ursinus racketeers stumble • Haverford beaten second time, 6-2 • UC shears Ewes • Bears drop Shoremen from undefeated ranks • Lacrosse team drops WC, 6-4https://digitalcommons.ursinus.edu/weekly/1296/thumbnail.jp

The Ursinus Weekly, March 9, 1964

Junior Prom and Agency concert highlight coming weekend • Curtain Club chooses cast; Meridy Murphy will direct Remarkable Mr. Pennypacker • Kaffee Klatsch topic politics • Sig Nu and ZX win Songfest • Photo contest • Wedgwood, controversial historian, author, here Wednesday evening • Campus Chest plans underway • Red Cross seeking qualified swimmers • 1,100 applications filed at UC for Fall admissions • Jean Hunter, Howard Smith elected Ruby co-editors • March placement schedule posted • Ursinus to raise tuition rate $200 effective Sept. 1 • Review: Mr. Lincoln on civil rights • Navy OCS team will visit campus next week • Letters to the editor • Fall of man topic of Bible Study • Genevieve Blatt: Our role in politics • Dateline: Stockholm • Greek gleanings • Modern tri-mesters used in 1880 here • Girls BB falls to ES, 46-36; JV team continues unbeaten • West Chester wins intercollegiates • Mermaids lose in two close meets • Wrestling: Win last match • Hofmann receives sportswriter\u27s award • MAC tournamenthttps://digitalcommons.ursinus.edu/weekly/1267/thumbnail.jp

Approaches to Case Management with Substance Abusing Populations

This chapter is from the book Addictions: Concepts and Strategies for Treatment, which explores the views of dozens of leading experts in the addictions field. It combines current theory and innovative practice for treating and preventing a broad spectrum of addictive behaviors, including alcohol abuse, drug abuse, tobacco abuse, eating disorders and gambling. Using a family-centered approach, Addictions offers in-depth coverage of exciting new ideas and strategies currently being used in practice

Potential approaches for more successful dendritic cell-based immunotherapy.

INTRODUCTION: Dendritic cells (DCs) are the most important antigen-presenting cell population for activating antitumor T-cell responses; therefore, they offer a unique opportunity for specific targeting of tumors. AREAS COVERED: We will discuss the critical factors for the enhancement of DC vaccine efficacy: different DC subsets, types of in vitro DC manufacturing protocol, types of tumor antigen to be loaded and finally different adjuvants for activating them. We will cover potential combinatorial strategies with immunomodulatory therapies: depleting T-regulatory (Treg) cells, blocking VEGF and blocking inhibitory signals. Furthermore, recommendations to incorporate these criteria into DC-based tumor immunotherapy will be suggested. EXPERT OPINION: Monocyte-derived DCs are the most widely used DC subset in the clinic, whereas Langerhans cells and plasmacytoid DCs are two emerging DC subsets that are highly effective in eliciting cytotoxic T lymphocyte responses. Depending on the type of tumor antigens selected for loading DCs, it is important to optimize a protocol that will generate highly potent DCs. The future aim of DC-based immunotherapy is to combine it with one or more immunomodulatory therapies, for example, Treg cell depletion, VEGF blockage and T-cell checkpoint blockage, to elicit the most optimal antitumor immunity to induce long-term remission or even cure cancer patients

In vivo cancer vaccination: Which dendritic cells to target and how?

The field of cancer immunotherapy has been revolutionized with the use of immune checkpoint blockade antibodies such as anti-programmed cell death 1 protein (PD-1) and chimeric antigen receptor T cells. Significant clinical benefits are observed in different cancer types with these treatments. While considerable efforts are made in augmenting tumor-specific T cell responses with these therapies, other immunotherapies that actively stimulate endogenous anti-tumor T cells and generating long-term memory have received less attention. Given the high cost of cancer immunotherapies especially with chimeric antigen receptor T cells, not many patients will have access to such treatments. The next-generation of cancer immunotherapy could entail in vivo cancer vaccination to activate both the innate and adaptive anti-tumor responses. This could potentially be achieved via in vivo targeting of dendritic cells which are an indispensable link between the innate and adaptive immunities. Dendritic cells highly expressed toll-like receptors for recognizing and eliminating pathogens. Synthetic toll-like receptors agonists could be synthesized at a low cost and have shown promise in preclinical and clinical trials. As different subsets of human dendritic cells exist in the immune system, activation with different toll-like receptor agonists could exert profound effects on the quality and magnitude of anti-tumor T cell responses. Here, we reviewed the different subsets of human dendritic cells. Using published preclinical and clinical cancers studies available on PubMed, we discussed the use of clinically approved and emerging toll-like receptor agonists to activate dendritic cells in vivo for cancer immunotherapy. Finally, we searched www.clinicaltrials.gov and summarized the active cancer trials evaluating toll-like receptor agonists as an adjuvant